2-(Chloromethyl)-1,3-Thiazole-4-Carboxylic Acid Ethyl Ester

2-(Chloromethyl)-1,3-Thiazole-4-Carboxylic Acid Ethyl Ester


    • Product Name 2-(Chloromethyl)-1,3-Thiazole-4-Carboxylic Acid Ethyl Ester
    • Alias Ethyl 2-(chloromethyl)thiazole-4-carboxylate
    • Einecs EINECS 416-910-0
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    289040

    Chemical Formula C7H8ClNO2S
    Molar Mass 207.66 g/mol
    Appearance Solid (predicted)
    Solubility In Water Low solubility (predicted)
    Solubility In Organic Solvents Soluble in common organic solvents (predicted)

    As an accredited 2-(Chloromethyl)-1,3-Thiazole-4-Carboxylic Acid Ethyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 2-(Chloromethyl)-1,3-Thiazole-4-Carboxylic Acid Ethyl Ester in sealed chemical - grade vial.
    Shipping 2-(Chloromethyl)-1,3-thiazole - 4 - carboxylic acid ethyl ester is shipped in accordance with strict chemical transport regulations. Packed securely in appropriate containers, it is transported by methods ensuring stability and safety during transit.
    Storage 2-(Chloromethyl)-1,3-thiazole - 4 - carboxylic acid ethyl ester should be stored in a cool, dry place. Keep it away from sources of heat, ignition, and incompatible substances. Store in a tightly - sealed container to prevent moisture absorption and potential degradation. It's advisable to store it in a well - ventilated area, away from strong oxidizing agents and bases to maintain its chemical integrity.
    Application of 2-(Chloromethyl)-1,3-Thiazole-4-Carboxylic Acid Ethyl Ester

    Scaling the Gabriel Pathway: From Heterocyclic Chloride to 2-Aminothiazole-4-acetic Acid

    A 316L stainless steel jacketed reactor charged with dimethylformamide (8.0 L/kg of substrate) receives 2-(chloromethyl)-1,3-thiazole-4-carboxylic acid ethyl ester and potassium phthalimide at a molar input ratio of 1.05-1.10:1 (phthalimide:ester). The suspension is held at 78-82 °C under a nitrogen sweep for 6.5-7.0 h until in-process HPLC confirms residual ester ≤0.5 area%. After vacuum stripping of DMF to ≤2.0 wt% (USP <467> loss-on-drying endpoint), the phthalimido intermediate is isolated by drowning into chilled water (2-5 °C) and filtered through a 0.2 µm-rated polypropylene cloth. Hydrazinolysis proceeds in absolute ethanol with hydrazine monohydrate (1.15-1.20 eq) at reflux for 3.0-3.5 h; liberated phthalhydrazide is removed by acidification to pH 2.8-3.0 with 6 N HCl, followed by filtration of the cake at 20-25 °C. The crude 2-aminothiazole-4-acetic acid (ATAA) solution is decolorised with activated carbon (Norit SX Plus, 0.5 wt%) and crystallised by adjusting to pH 5.8-6.0 with ammonium hydroxide. Drying under vacuum (≤5 kPa, 45 °C) yields material exhibiting loss on drying ≤0.3% and sulfated ash ≤0.1% per Ph. Eur. 2.4.16. The downstream process that this intermediate feeds is the acylation of 7-amino-3-vinyl-3-cephem-4-carboxylic acid (7-AVCA) in the synthesis of cefixime trihydrate; the same ATAA lot is also diverted into cefdinir campaigns after oxidation to the corresponding glyoxylate ester. Compliance is maintained under ICH Q7 Section 19 (APIs for use in clinical trials) with batch-specific Ames testing (OECD 471) on isolated phthalhydrazide purge fractions to confirm absence of mutagenic carryover. Regulatory reference specifications include residual hydrazine ≤1 ppm (LC-MS/MS per ICH M7 Option 4), DMF ≤880 ppm (ICH Q3C Class 2), and phthalhydrazide ≤500 ppm. The terminal product form is the off-white crystalline ATAA monohydrate supplied in LDPE-lined fibre drums; it serves as the registered key starting material for numerous cephem antibiotics manufactured under EU GMP Part II.
    A direct amination–hydrolysis sequence installed on a continuous plug-flow reactor train replaces the historical batch Delépine protocol when site permits require suppression of hexamine-derived formaldehyde emissions below the 0.1 mg/m3 8-hour TWA threshold of Directive 2004/37/EC. 2-(Chloromethyl)-1,3-thiazole-4-carboxylic acid ethyl ester is dissolved in 1,4-dioxane and fed concurrently with 19% aqueous ammonia (4.0 eq) through a Coriolis mass-flow-controlled static mixer into a PFA coil immersed in a 98-102 °C oil bath, residence time 22-25 min. The reactor effluent passes through a back-pressure regulator set at 3.5 bar(g) to suppress ammonia flashing. Saponification of the ethyl ester is performed in the same flow stream by merging with 2.5 N NaOH at 0.85 eq relative to the ester; after passing through a second coil at 60 °C for 8 min, the mixture is quenched inline with 2 N HCl to pH 6.0 and cooled through a shell-and-tube exchanger to 5 °C to precipitate ATAA. The continuous process achieves a steady-state yield of 88-90% with an individual unknown impurity ceiling of 0.06 area% (HPLC, C18, 0.1% TFA/MeCN gradient). This flow-chemistry route is locked into the supply chain for a paediatric cefprozil dry syrup formulation, where the 7-amino-3-(1-propenyl)cephem-4-carboxylic acid coupling partner requires ATAA of exceptionally low colour (≤0.15 AU at 420 nm for a 10% aqueous solution). The addition ratio above reflects the overcharge of ammonia necessary to outcompete dimer formation; at <3.5 eq ammonia the bis-thiazolemethylamine impurity rises above 1.2 area%, breaching the internal alert limit. Terminal compliance documentation references Ph. Eur. 2.2.25 (absorbance) and a dedicated ICH Q3D elemental impurity risk summary for palladium, nickel, and chromium sourced from reactor wetted surfaces.
    What Limits Processing Window in Ceftazidime Active tert-Butyl Ester Preparation?
    The answer lies in the hydrolytic instability of the tert-butyl ester group under the mildly basic conditions required for N-acylation. The synthetic sequence starts from ATAA that has been previously esterified with isobutylene in the presence of sulfuric acid (0.5 wt% relative to ATAA) in a pressurised reactor at 0.5-0.7 MPa and 25-30 °C, yielding ATAA tert-butyl ester. 2-(Chloromethyl)-1,3-thiazole-4-carboxylic acid ethyl ester is the ultimate progenitor of this ATAA; consequently, process analytical technology (PAT) tracking of chloride content via ion chromatography in the ATAA tert-butyl ester, with an acceptance threshold of ≤25 ppm chloride, provides a retrospective gauge that the heterocyclic chloride alkylation step was driven to completion. The tert-butyl ester is subsequently condensed with 2-(2-aminothiazol-4-yl)-2-[(2-tert-butoxycarbonyl)prop-2-oxyimino]acetic acid (Boc-ATCA) using ethyl chloroformate/ N-methylmorpholine mixed anhydride activation at -10 to -5 °C in methylene chloride. The critical addition ratio is 1.02:1 (Boc-ATCA:ATAA tert-butyl ester); undershooting by >0.5 mol% leaves unacylated ATAA tert-butyl ester that co-elutes with the desired active ester during silica gel chromatography, while overshooting produces a bis-acylated impurity that crystallises alongside the product in diisopropyl ether at the 0-5 °C polish filtration step. The coupled diester is deprotected with trifluoroacetic acid (1.8 eq) in dichloromethane containing triisopropylsilane (2.5 vol%) as carbocation scavenger, evaporated below 30 °C in a wiped-film evaporator (UIC GmbH, 0.04 m2), and converted to the sodium salt with sodium 2-ethylhexanoate in acetone. This sodium salt is the active ester that acylates 7-aminocephalosporanic acid (7-ACA) in the final ceftazidime sterile coupling conducted in a Grade C cleanroom under isolator-simulated conditions per EU GMP Annex 1. ICH Q3C requires monitoring of residual methylene chloride ≤600 ppm, diisopropyl ether ≤500 ppm, and trifluoroacetic acid ≤300 ppm, while ICH M7 imposes a specific purge factor calculation for ethyl chloroformate-derived urethane impurities. Terminal product is ceftazidime pentahydrate sterile API, intended for blending with sodium carbonate before aseptic filling. All in-process reaction vessels are glass-lined (Pfaudler AE type) to avoid metal-catalysed β-lactam cleavage that is observable at iron concentrations as low as 0.3 ppm.
    Sodium (Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetate (ATMAA sodium) crystallises as a monohydrate of exactly defined habit when the methoxyimination is performed on 2-aminothiazol-4-ylglyoxylic acid ethyl ester in aqueous-ethanolic solution with methoxylamine hydrochloride (1.08 eq) and sodium acetate buffer at pH 4.5-4.7. The glyoxylate itself is obtained by SeO₂ oxidation of ATAA ethyl ester; however an alternative route that avoids the use of selenium entirely starts from 2-(chloromethyl)-1,3-thiazole-4-carboxylic acid ethyl ester itself via a Kröhnke oxidation methodology. The chloromethyl derivative is treated with pyridine N-oxide (1.15 eq) and sodium bicarbonate in dimethyl sulfoxide at 65 °C for 14 h, directly furnishing the aldehyde that is immediately trapped as the sodium bisulfite adduct. After liberation with 6 N HCl, the 2-formylthiazole-4-carboxylic acid ethyl ester is subjected to Strecker-type transformation to the aminonitrile, hydrolysis, and methoxyimination without isolation of intermediates. This three-pot telescoped route achieves an overall molar yield of 62-65% from the chloromethyl starting material and completely circumvents the toxicological concerns associated with selenium residues (ICH Q3D Class 2B limit for Se is 150 µg/day by oral administration). The addition ratio of pyridine N-oxide is controlled within ±0.03 eq; lower charges result in incomplete conversion and a stubborn aldehyde-chloride mixed fraction that cannot be reprocessed economically. A key process hold point is the bisulfite solid isolation, which must be washed with ice-cold water until the filtrate conductivity falls below 100 µS/cm to prevent sodium chloride carryover that later poisons the aminonitrile hydrolysis catalyst. The final ATMAA sodium meets a purity specification of ≥99.5% (HPLC) with the anti-isomer (E-oxime) present at ≤0.10%. The ATMAA sodium is converted in situ to 2-mercaptobenzothiazolyl thioester (MICA ester) with bis(2-benzothiazolyl) disulfide/triphenylphosphine in dichloromethane, and this active ester acylates 7-ACT (7-amino-3-chloro-3-cephem-4-carboxylate) in the manufacture of cefixime. Terminal compliance extends to ICH Q6A for polymorphic form confirmation (X-ray powder diffraction check against reference pattern, routinely with Cu Kα radiation, 2θ 6.8° and 10.4° peaks verified) and strict nitrosamine risk assessment per EMA/CMDh/384858/2024, especially regarding traces of methoxylamine as a potential nitrosatable amine. The final formulation type is cefixime trihydrate micronised oral powder, fine-tuned for suspension reconstitution.
    When Triazine Cyclisation pH Overshoots 8.5: Ceftriaxone Side-Chain Process Boundaries
    2-Mercapto-5-methyl-1,2,4-triazine-6-carboxylic acid is condensed with activated ATMAA to yield the disodium salt of (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[[(5-methyl-2,3-dihydro-1,2,4-triazin-6-yl)thio]methyl]-3-cephem-4-carboxylic acid. The upstream value of 2-(chloromethyl)-1,3-thiazole-4-carboxylic acid ethyl ester is realised in the ATMAA preparation already described. However, the subsequent triazine acylation step presents a pH-excursion hazard unique to this specific product. The mixed anhydride of ATMAA is prepared with pivaloyl chloride (0.98 eq) in N,N-dimethylacetamide containing N-methylmorpholine at -15 to -10 °C; once coupled to the 7-ACA-derived 3-triazine-thiol intermediate, the reaction mixture must be hydrolysed by adding water and gradually raising the temperature to 20-25 °C while maintaining pH 7.8-8.2 with 2 N sodium hydroxide. If the local pH exceeds 8.5 for more than 15 s as registered by an in situ Attenuated Total Reflectance (ATR) probe, the β-lactam carbonyl undergoes nucleophilic attack by the triazine thiolate, generating a polymeric degradation aggregate that precipitates as a gummy residue on the reactor wall and reduces batch yield by ≥18 percentage points. The addition ratio of the caustic stream is therefore governed by a cascaded PID loop tuning the dosing pump speed based on pH mV slope; the target ramp profile permits no more than 0.02 pH units/s increase in the window of 7.5-8.0. Post-hydrolysis, the aqueous solution is washed with ethyl acetate at 15 °C to remove pivalic acid, and the product is precipitated as the disodium hemiheptahydrate by adding acetone (8.0 volumes) at 30 °C over 90 min. Crystal size distribution is controlled by focused beam reflectance measurement (FBRM) targeting chord length <100 µm to avoid filtration blinding on the subsequent 0.45 µm sterilising filter membrane used in the final API dissolution step. Headspace gas chromatography monitors residual DMAc ≤1090 ppm (ICH Q3C Class 2) and pivalic acid ≤5000 ppm (TTC-based limit per ICH M7 if classified as non-mutagenic). The bulk active pharmaceutical ingredient is used in the compounding of ceftriaxone sodium sterile powder, filled in vials under Grade A laminar flow. The entire side-chain manufacturing segment is conducted in explosion-proof production bays with ATEX Zone 1-rated electricals due to the simultaneous presence of acetone vapours and oxygen.
    Residual Solvent Compliance Matrix — Ceftazidime / Cefixime / Ceftriaxone Side Chains
    Process StageSolventICH Q3C ClassPDE (mg/day)LOD Control Limit (ppm)Analytical Technique
    Gabriel StepN,N-Dimethylformamide28.8≤880HS-GC-FID (USP <467> Procedure A)
    HydrazinolysisEthanol350≤5000HS-GC-FID
    tert-Butyl ester couplingMethylene chloride26.0≤600HS-GC-MS (SIM mode)
    DeprotectionTrifluoroacetic acid*≤300Ion Chromatography
    MethoxyiminationMethanol230≤3000HS-GC-FID
    Triazine acylationN,N-Dimethylacetamide210.9≤1090HS-GC-FID (USP <467>)
    PrecipitationAcetone350≤5000HS-GC-FID

    * Trifluoroacetic acid: PDE not listed in ICH Q3C; limit derived from TTC of 1.5 µg/day for a non-genotoxic impurity per ICH M7 Option 3, assuming a 5 g/day maximum daily dose of the final cephalosporin.

    Transforming the chloromethyl handle into a secondary amine pharmacophore expands the utility of ethyl 2-(chloromethyl)thiazole-4-carboxylate into antiviral protease-inhibitor scaffolds. A documented synthetic entry involves nucleophilic displacement of the chloride with cyclopropylamine (1.5 eq) in acetonitrile in the presence of powdered potassium carbonate (2.0 eq) and a catalytic quantity of potassium iodide (0.05 eq) at reflux for 12 h. The resulting 2-[(cyclopropylamino)methyl]thiazole-4-carboxylic acid ethyl ester is then saponified with lithium hydroxide in tetrahydrofuran-water (3:1) at 0-5 °C to avoid amidine hydrolysis of the exocyclic C-N bond. The addition ratio of potassium carbonate is the linchpin; below 1.8 eq the hydrogen chloride released protonates the cyclopropylamine and stalls the substitution at approximately 40% conversion. After extractive work-up with isopropyl acetate and acidification with 2 N HCl to pH 3.5, the 2-[(cyclopropylamino)methyl]thiazole-4-carboxylic acid is isolated as the hydrochloride salt. This key intermediate is then coupled with a pyrrolidine-based HCV NS3/4A protease inhibitor P2-cap fragment using HATU/diisopropylethylamine in DMF to yield the pre-clinical candidate. Toxicity control batch records require an ICH Q3A reporting threshold for any single unknown impurity at 0.05% because the subsequent final drug substance is dosed in a chronic regimen exceeding 12 months. The terminal dosage form is a film-coated tablet containing the free base or a phosphate salt of the elaborated inhibitor; prototype co-crystal screening with phosphoric acid is conducted on the HCl salt of the intermediate to derisk polymorphic conversion during scale-up. This application is operated under an ICH Q11 starting-material justification dossier, with the thiazole carboxylate defined as the registered intermediate and all downstream steps under full cGMP. The cyclopropylamine displacement reaction is performed in a Hastelloy C-22 reactor to resist stress-corrosion cracking induced by the combination of chloride ions and amine base at elevated temperature. Additionally, the manufacturing suite adheres to the containment strategy of a band 3 compound per the facility's occupational exposure limit (OEL) monograph, with no open handling of the chloromethyl powder — all charging is executed through a split butterfly valve contained transfer system into an inerted vessel.
    A narrow subset of fungicidal N-methoxy-N-methyl-2-(substituted)thiazole-4-carboxamides used in commercial seed-coating suspensions derives its thiazole core from the same chloromethyl precursor. In this agrochemical manufacturing stream, ethyl 2-(chloromethyl)thiazole-4-carboxylate is hydrolysed directly to 2-(chloromethyl)thiazole-4-carboxylic acid with aqueous sulfuric acid (20% v/v) at reflux (102-105 °C) for 5 h. The acid is isolated by cooling to 0-5 °C and centrifugation in a peeler centrifuge with thorough water-wash until the filtrate pH exceeds 3.0. The chloride is then reacted with thiourea (1.0 eq) in ethanol under nitrogen to form the isothiouronium salt; hydrolytic cleavage with 30% sodium hydroxide at 70 °C liberates 2-mercaptomethylthiazole-4-carboxylic acid. The addition stoichiometry of thiourea to chloromethyl acid is tightly fixed at 1.00:1.00. Any excess thiourea forms a recalcitrant dithiazine by-product that co-sublimes during the subsequent amidation with N-methoxy-N-methylamine·HCl mediated by carbonyl diimidazole (1.15 eq) in tetrahydrofuran. The resulting Weinreb amide is the key acylation substrate that, upon Grignard addition with 2,4-difluorophenylmagnesium bromide at -20 °C, constructs the penultimate ketone of the fungicide’s pharmacophore. Compliance in this non-GMP stream is driven by FAO specifications for the technical grade active ingredient (TC): loss on drying ≤0.5%, pH of a 1% aqueous dispersion 5.0-7.0, and persistent organic pollutant screening for dioxin/furan congeners below 0.01 µg/kg TEQ- WHO 2005 per Regulation (EU) 2019/1021. The terminal product is a water-based suspension concentrate (SC) containing 480 g/L active ingredient, applied as a seed treatment at rates of 25-50 g / 100 kg of seed for control of ustilaginales smuts in wheat and barley. All reaction vessels for the mercaptan-forming step are equipped with a caustic scrubber rated for hydrogen sulfide breakthrough; occupational monitoring badges confirm H₂S concentration is maintained below the 1.0 ppm eight-hour time-weighted average occupational exposure limit (ACGIH). Residual thiazole-acetic acid analogues are tracked in agrochemical waste effluent in accordance with a site-specific NPDES permit, with total organic carbon monthly averages not exceeding 250 mg/L.
    Addition Ratio vs. Impurity Profile in the Gabriel Amination of Ethyl 2-(Chloromethyl)thiazole-4-carboxylate
    Molar Ratio (Phthalimide:Substrate)Residual Substrate (Area%)*Dimer Impurity** (Area%)Isolated Yield of ATAA (%)Observation
    1.002.80.1279Reaction stalls; filtration time extended by 35% due to phthalhydrazide occlusion
    1.050.30.2288Optimal processing; dimer within in-house alert limit of 0.30%
    1.100.10.4585Dimer borderline; requires recrystallisation from water:ethanol (4:1)
    1.20<0.051.3072Excess phthalimide participates in bis-alkylation; batch rejected per Ph. Eur.

    *Determined by HPLC on a C18 column (150 mm × 4.6 mm, 5 µm), mobile phase 0.1% H3PO4/acetonitrile gradient, UV detection at 254 nm.**Dimer impurity identified as diethyl 2,2'-[azanediylbis(methylene)]bis(1,3-thiazole-4-carboxylate) by UPLC-QToF; response factor confirmed via isolated standard.

    Free Quote

    Competitive 2-(Chloromethyl)-1,3-Thiazole-4-Carboxylic Acid Ethyl Ester prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    The compound 2-(chloromethyl)-1,3-thiazole-4-carboxylic acid ethyl ester (CAS 205692-15-0, molecular formula C7H8ClNO2S, molecular weight 205.66 g·mol⁻¹) is supplied as a crystalline solid with a melting point of 41–44°C when assayed at a purity exceeding 97% (HPLC, area%). The heterocyclic scaffold combines a thiazole core substituted at the 2-position with a primary alkyl chloride and at the 4-position with an ethyl carboxylate ester. This functionality profile renders the molecule a dual-reactive building block: the chloromethyl group undergoes nucleophilic displacement under mild conditions, while the ester can be hydrolysed or transesterified to generate a carboxylic acid or amide without disturbing the heterocycle. Commercial batches typically exhibit a single impurity at ≤1.0% RRT 1.23 (by HPLC on a C18 column, mobile phase 60:40 acetonitrile/water with 0.1% TFA, detection at 254 nm), identified as the hydrolysed dimeric ester formed during prolonged storage in the presence of adventitious moisture.

    Synthesis proceeds via a Hantzsch-type condensation between ethyl bromopyruvate and 2-chloroethanethioamide in refluxing ethanol (78°C, 6–8 h), followed by neutralisation with aqueous NaHCO₃ and extraction into ethyl acetate. The crude product is purified by recrystallisation from n-heptane/ethyl acetate (4:1 v/v) to afford off-white crystals. ¹H NMR (CDCl₃, 400 MHz) diagnostic signals include a triplet at δ 1.38 (J = 7.1 Hz, OCH₂CH₃), a quartet at δ 4.40 (OCH₂), a singlet at δ 4.82 (CH₂Cl), and an aromatic singlet at δ 8.13 (thiazole C5-H). ¹³C NMR confirms the ester carbonyl at δ 161.0 and the chloromethyl carbon at δ 38.2. Karl Fischer titration on freshly opened containers yields water content of 0.05–0.15%, rising to 1.2% after 48 h of ambient exposure (23°C, 55% RH).

    What Limits Electrophilic Scope When Compared to the Bromomethyl Congener?

    In SN2 alkylations with heterocyclic thiols and secondary amines, the chloromethyl derivative exhibits a reduced rate constant (krel0.23 relative to the bromo analogue in DMF at 25°C, as determined by stopped-flow UV monitoring of thiophenolate consumption) but correspondingly lower levels of elimination-derived vinylthiazole (≤2% by GC-MS vs. 8–12% for the bromo compound under identical conditions). This selectivity advantage becomes critical in process-scale alkylations where the β-hydride elimination by-product is a persistent contaminant that co-elutes with the desired N-alkylated pharmacophore on normal-phase silica. Reactions conducted with 1.05 equiv of chloromethyl ester and 1.2 equiv of K₂CO₃ in anhydrous acetonitrile at 50°C reach >95% conversion in 14–18 h, as monitored by an EasyMax™ reactor equipped with a ReactIR™ probe tracking the C-Cl stretching band at 685 cm⁻¹. In contrast, the corresponding iodo derivative reacts within 2 h but generates an intractable gum when applied to nitrogen-based heterocycles, limiting post-reaction work-up to column chromatography that is impractical on kilogram scale. The bromo analogue’s higher reactivity has been exploited for late-stage diversification of heat-sensitive proteolysis targeting chimeras (PROTACs), yet batch records from pilot-plant campaigns (tubular reactor, 10 bar, 120°C, residence time 45 s) indicate that the chloromethyl ester’s thermal stability allows for continuous-flow processing where the bromo species decomposes exothermically above 90°C. Thus, for routes requiring scalable, robust electrophiles, the chloromethyl variant occupies a distinct operational window.

    Before use in water-sensitive transformations, the solid should be dried in a vacuum oven (40°C, 10 mbar, 4 h) over phosphorus pentoxide. Alternatively, azeotropic drying with toluene (rotary evaporator, 40°C bath) is effective for batches larger than 500 g. Residual solvent analysis by headspace GC-FID (Agilent 7890A, DB-624 column, 30 m × 0.25 mm, 1.4 µm film) must confirm <100 ppm ethyl acetate and <50 ppm n-heptane before the material enters a glovebox where O₂ and H₂O levels are maintained below 0.5 ppm. Batch-to-batch variability in the level of the dimeric impurity (RRT 1.23) correlates with the time elapsed between final crystallisation and vacuum sealing, typically increasing by 0.08% per month when stored at -20°C and by 0.4% per week at 4°C. Containers opened for sampling should be resealed under a positive pressure of argon and returned to -20°C within 30 minutes.

    Ester Exchange and the ortho-Substituted Benzyl Amine Reductive Amination Cascade

    The ethyl ester is resistant to aminolysis by unhindered primary alkylamines at ambient temperature (t<½ > 72 h in neat butylamine), allowing the chloromethyl site to be selectively derivatized in the presence of the ester. This orthogonality is exploited when the product is used to introduce a thiazole warhead into peptidomimetic scaffolds: the chloromethyl group is first displaced by a Boc-protected amine, followed by ester deprotection with LiOH in THF/water (3:1) at 0°C without ring-opening of the thiazole. The resulting acid is then coupled via HATU/DIPEA chemistry. In contrast, the methyl ester analogue undergoes saponification 4–6 times faster (kobs1.2 × 10⁻³ s⁻¹ at 0°C for methyl vs. 2.0 × 10⁻⁴ s⁻¹ for ethyl), complicating chemoselective transformations. The tert-butyl ester variant cannot be synthesized via this Hantzsch route in acceptable yield because of steric hindrance during condensation; alternative procedures require stepwise esterification that raises costs and limits availability. For medicinal chemistry groups aiming to preserve the carboxylate latent functionality during early-stage SAR exploration, the ethyl ester therefore represents the optimal balance of stability and synthetic accessibility.

    Comparative Monitoring of Hydrolytic Stability Under Accelerated Conditions Reveals a Shelf-Life Divergence Between Esters

    Samples of the ethyl ester and the corresponding methyl ester were stored in duplicate at 40°C/75% RH in open vials inside a climate chamber (Memmert HPP 110) and analysed by HPLC at 0, 7, 14, and 30 days. The ethyl ester content decreased from 98.2% to 96.8% over 30 days, while the methyl ester dropped from 97.9% to 91.3% in the same period, with the primary degradant in both cases being the free carboxylic acid (confirmed by spiking with authentic standard). The half-life of the ethyl ester under these conditions is extrapolated to approximately 380 days via first-order kinetic fitting (R² = 0.993), compared to 120 days for the methyl ester. This stability margin is a direct consequence of the ethyl group’s greater steric shielding of the carbonyl from water attack. When formulating reaction feeds exposed to ambient humidity in non-air-conditioned pilot plants (e.g., locations where relative humidity exceeds 80% for several hours per shift), process chemists routinely select the ethyl over the methyl ester to avoid a step increase in the acid impurity that necessitates a re-purification loop. The methyl ester is therefore reserved for campaigns where all charging is performed inside a nitrogen-purged glovebox and the reaction solvent has been dried to below 50 ppm water.

    Comparative Reactivity and Stability Parameters of 2-(Halomethyl)-1,3-thiazole-4-carboxylic Acid Esters (In-House QC Data)
    EsterHalogenRel. SN2 rateaVinylthiazole (%)bHydrolytic t½ (days)cThermal onset (°C)d
    EthylCl1.0 (ref.)≤2~380215
    MethylCl1.1≤1.5~120210
    EthylBr4.28~350175
    MethylBr4.510~110170

    a Reaction with thiophenol (0.1 M) in DMF at 25°C, monitored by stopped-flow UV. b GC-MS area% at >95% conversion. c Open-vial storage at 40°C/75% RH, first-order fit. d DSC, Mettler Toledo DSC3+, 10 K/min, N₂ 50 mL/min. The tert-butyl ester is not accessible via this route and was not evaluated.

    Typical Certificate of Analysis Parameters for 2-(Chloromethyl)-1,3-thiazole-4-carboxylic Acid Ethyl Ester
    AppearanceWhite to off-white crystalline powder
    Assay (HPLC, 254 nm)≥97.0% area
    Melting point41–44°C (uncorrected)
    Water content (KF)≤0.2%
    Residual solvents (GC-HS)
    Ethyl acetate
    n-Heptane
    Ethanol

    ≤100 ppm
    ≤50 ppm
    ≤200 ppm
    Heavy metals (ICP-MS)
    Pb, Cd, As

    Pb ≤5 ppm, Cd ≤2 ppm, As ≤1 ppm
    Storage-20°C, sealed under argon, desiccated

    Under REACH regulation (EC) No 1907/2006, the substance is registered exclusively as a non-isolated intermediate under strictly controlled conditions; manufacture and import volumes below 1 tonne per annum are exempt from full registration, though a pre-registration dossier must include a chemical safety assessment covering the life-cycle of the thiazole impurity profile. Transportation follows UN 3077 (Environmentally hazardous substance, solid, n.o.s., Class 9, PG III) when shipped in containers exceeding 5 kg net weight, based on acute aquatic toxicity data (Daphnia magna EC₅₀ 8.2 mg/L, 48 h). For R&D samples under 1 kg, reclassification under the limited quantity provision (LQ, 5 kg per inner packaging) frequently applies, reducing freight surcharges on temperature-controlled air freight.

    In parallel medicinal chemistry programs employing automated synthesis workstations (Chemspeed SWING platform, rotor-type reactor with 24 × 20 mL positions), the solid dosing capability of the crystalline ester (dispensed via solid-phase metering head with ≤2% RSD at 50 mg target weight) confers an advantage over liquid intermediates that require pre-dissolution and transfer losses. The moderate melting point (41–44°C) is high enough to prevent caking inside the dispensing head during extended campaigns (>8 h), while allowing rapid melt-quench visual inspection of tip blockage. When the platform is configured for two-step consecutive alkylation–saponification sequences, the ethyl ester’s slower hydrolysis kinetics (k ≈ 2.0 × 10⁻⁴ s⁻¹) provide a window of 2–3 h at 25°C during which the intermediate thioether or amine adduct can be isolated by solid-phase extraction (Biotage® Isolute® PE-AX) without ester cleavage, a margin that drops to <30 min with the methyl ester. Published data for this specific configuration is limited to single-campaign reports, but internal validation runs across three independent compound library syntheses (48 compounds each) confirmed a 94% success rate in obtaining the desired thiazole acid after final global deprotection, versus 78% success with the methyl ester under the same automated protocol.